Chimerix Inc

Chimerix — Investor Presentation (December 2024)

39 slides from Chimerix's investor presentation, Dec 10, 2024

  1. Slide 1: Chimerix Corporate Presentation

    Chimerix Corporate Presentation December 10, 2024

  2. Slide 2: Forward-Looking Statements

    2 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking stateme

  3. Slide 3: Investment Highlights and Key Catalysts

    3 Investment Highlights and Key Catalysts Dordaviprone U.S. NDA submission planned for Dec ‘24, potential U.S. accelerated approval in 2025  No approved therapies currently in recurrent H3 K27M diffuse glioma, an invariably lethal Grade 4 glioma (World Health Org)  Total addressable market exceeds

  4. Slide 4: Deep Pipeline Across All Development Stages

    4 Program Preclinical Phase 1 Phase 2 Registrational Regulatory Approval Deep Pipeline Across All Development Stages Dordaviprone (ONC201) Front line (ACTION study) H3 K27M-mutant diffuse glioma IITs- multiple oncology studies CMX521 Novel coronaviruses Central Nervous System tumors ONC206 IND-enabl

  5. Slide 5: Dordaviprone: H3 K27M-mutant diffuse glioma

    Dordaviprone: H3 K27M-mutant diffuse glioma

  6. Slide 6: About H3 K27M-mutant Diffuse Glioma

    6 • Highly aggressive and classified as WHO Grade 4 • U.S. incidence >2,000 - most frequently occurs in children and young adults1 • Surgical resection limited due to location • Effective treatment limited to radiotherapy, invariably recurs • No approved therapies for H3 K27M-mutant glioma currently

  7. Slide 7: Recent program milestones

    7 Recent program milestones include: • Substantial enrollment of the Phase 3 ACTION study • 50-patient primary efficacy analysis using multiple response criteria, including the most recently established response criteria for glioma, Response Assessment in Neuro Oncology (RANO) 2.0 • Responders had c

  8. Slide 8: Primary efficacy analysis objective and eligibility

    8 Objective • To evaluate monotherapy efficacy of dordaviprone in recurrent H3 K27M-mutant diffuse midline glioma by dual-reader blinded independent central review (BICR) in first 50 subjects who meet the following eligibility criteria agreed to with U.S. FDA Eligibility • Age ≥2yo and received dord

  9. Slide 9: Response results in 50-patient efficacy analysis

    9 n=50 RANO 2.0 RANO-HGG RANO-LGG Objective Response Rate, n (%) [95% CI] 14 (28.0) [16.2-42.5] 10 (20.0) [10.0-33.7] 13 (26.0) [14.6-40.3] Complete Response 0 1 (2.0) 0 Partial Response 10 (20.0) 9 (18.0) 6 (12.0) Minor Response 4 (8.0) NA 7 (14.0) Stable Disease 6 (12.0)1 10 (20.0) 8 (16.0) Not Ev

  10. Slide 10: RANO 2.0 response associated with overall survival

    10 RANO 2.0 response as a time varying covariate was significantly associated with OS in a multivariate Cox Proportional Hazards model (HR [95% CI]: 0.22 [0.08 to 0.58]; p=0.0024) 1Best overall response by RANO criteria assessed by BICR. Not evaluable if PD with decreasing steroids or SD with increa

  11. Slide 11: 28% ORR by RANO 2.0

    11 * Change > 100%, PR=partial response, MR=minor response, SD=stable disease, NE=not evaluable, PD=progressive disease MRI type: T1 post-contrast1 MRI type: T2/FLAIR1 RANO 2.0 RANO 2.0 28% ORR by RANO 2.0 Evaluates Enhancing and Non-Enhancing Disease 1 50-patient primary efficacy analysis in recurr

  12. Slide 12: Clinical Pharmacology and Safety Assessment

    12 Clinical Pharmacology Studies n=245 • Dordaviprone was well tolerated at various dose levels (125 mg to 750 mg). • The majority of treatment-related adverse events across the clinical pharmacology studies were Grade 1 (mild) and transient. • Most common treatment-related AEs were grade 1 nausea a

  13. Slide 13: Dordaviprone FDA Designations

    13 Dordaviprone FDA Designations 1. Should the Company be awarded a Priority Review Voucher and thereafter sell such Priority Review Voucher to a third party, 50% of the net proceeds from such sale would be payable to the former security holders of Oncoceutics, Inc., pursuant the Agreement and Plan

  14. Slide 14: Dordaviprone Phase 3 ACTION Study Summary

    Dordaviprone Phase 3 ACTION Study Summary

  15. Slide 15: Pivotal Phase 3 ACTION Trial Design

    15 Now enrolling, a randomized, double-blind, placebo-controlled, multicenter international study in 450 newly diagnosed diffuse glioma patients whose tumor harbors an H3 K27M-mutation Pivotal Phase 3 ACTION Trial Design 1. Excludes DIPG and spinal tumors • H3 K27M-mutant diffuse glioma1 • Radiation

  16. Slide 16: ACTION Study Design Provides Multiple Paths for Success

    16 We Believe the ACTION Study Design Provides Multiple Paths for Success Interim data expected in third quarter of 2025 Second OS Interim • ~246 events • Success at HR~0.64 Final OS • ~327 events • Success at HR~0.73 PFS by RANO HGG(2) • ~286 events • Success at HR~0.68 1. Overall Survival (OS) 2.

  17. Slide 17: Dordaviprone Market Opportunity Assessment

    Dordaviprone Market Opportunity Assessment

  18. Slide 18: Market opportunity references and estimates

    18 (1) Ostrom QT, et al. Neuro Oncol. 2022;24(Suppl 5):v1-v95; (2) Patient numbers and percentages are estimates (weighted avg per sample size) derived from a review of the literature from (2012-2023): (Aihara K, et al. Neuro Oncol. 2014;16(1):140-6; Feng J, et al. Hum Pathol. 2015;46(11):1626-32; S

  19. Slide 19: Commercial Platform Expected Ready for Launch by Q3 2025

    19 Commercial Platform Expected to be Ready for Launch by Q3 2025, if NDA is Granted Unmet Need Patient Advocacy Patient Services & Distribution Access & Pricing Functional Expertise • Commercial Operations • Analytics & Insights • Pricing & Access • Distribution & Services • Marketing • Sales • Ult

  20. Slide 20: Launch Plan Enabled by Focused Commercial Infrastructure

    20 Specialized account teams embracing the patient community Focused efforts on concentrated centers of excellence and KOLs Optimized promotional effort throughout the neuro-oncology ecosystem Data-driven approach to drive investments and maximize effectiveness Scalable and flexible infrastructure t

  21. Slide 21: Dordaviprone Mechanism of Action

    Dordaviprone Mechanism of ActionDordaviprone Mechanism of Action

  22. Slide 22: Dordaviprone Directly Engages ClpP and DRD2

    22 • Dordaviprone can selectively induce apoptosis in cancer cells by altering the activity of two protein targets1 • ClpP agonism - Dordaviprone modifies ClpP conformation to increase degradation of mitochondrial proteins important for metabolism, epigenetics, and cancer cell viability • DRD2 antag

  23. Slide 23: Dordaviprone Reverses Central Hallmark of H3 K27M Glioma

    23 Dordaviprone Reverses Central Hallmark of H3 K27M-mutant Diffuse Glioma Mitochondrial effects of dordaviprone reverse H3 K27me3-loss Statistically significant H3 K27me3-loss reversal in dordaviprone-treated H3 K27M diffuse glioma patients https://aacrjournals.org/cancerdiscovery/article/13/11/237

  24. Slide 24: ONC206

    ONC206

  25. Slide 25: ONC206: Second Generation Oral Brain Penetrant ClpP Agonist + DRD2 Antagonist

    25 • 10x higher in vitro potency relative to dordaviprone • Monotherapy efficacy data observed across multiple preclinical models of Central Nervous System (CNS) and non-CNS tumors • Tumor regression in patient-derived xenografts • Oral dose escalation trials with intensified dosing nearing completi

  26. Slide 26: ONC206 Ph 1 Dose Escalation in Unselected CNS Tumors

    26 0 100 200 300 400 500 600 700 800 900 1000 1100 1200 1 2 3 4 5 6 7 8 9 10 11 O N C 20 6 m g/ w ee k Dose level 50 m g BI D 15 0 m g Q D 10 0 m g BI D 15 0 m g BI D 20 0 m g BI D 3 Once weekly dosing 3 consecutive days dosing 3 ONC206 Ph 1 Dose Escalation in Unselected CNS Tumors Enrolling Final C

  27. Slide 27: ONC206 Appears Well-Tolerated in Adult and Pediatric Patients

    27 ONC206 Appears Well-Tolerated in Adult and Pediatric Patients to Date 1. Adverse Events evaluable for safety. Data extraction from Adult study and Pediatric study as of Dec 2, 2024; preliminary data Related AEs1 Integrated Data Set N=100 All grades Grade ≥ 3 Any Treatment-related AE 49% 2% Fatigu

  28. Slide 28: ONC206 Dose Escalation and Intensification Well-Tolerated

    28 50mg QW N=10 100mg QW N=11 150mg QW N=12 200mg QW N=18 250mg QW N=14 350 mg QW N=33 50mg BID; TIW N=9 150mg QD; TIW N=14 100mg BID; TIW N=6 150mg BID; TIW N=33 200mg BID; TIW Weekly Dosing Multi-day/ week dosing Weekly Dose 2 50 mg 100 mg 150 mg 200 mg 250 mg 350 mg 300 mg 450 mg 600 mg 900 mg 12

  29. Slide 29: ONC206 Patient Exposures Exceeded Nonclinical Efficacy Exposures

    29 ONC206 Patient Exposures with Intensified Dosing Exceeded Exposures Associated with Nonclinical Efficacy 1. PK summary based on adult data; pediatric PK in DL 1-7 have been similar to adult 2. Average IC50 of 562 nM across 1088 cancer cell lines representing 25 tumor types 3. In vivo models inclu

  30. Slide 30: ONC206 Mechanism of Action and Preclinical Efficacy

    ONC206 Mechanism of Action and Preclinical Efficacy

  31. Slide 31: ONC206 Is a Second Generation Dual ClpP Agonist/DRD2 Antagonist

    31 • ClpP and DRD2 are direct binding targets that control mitochondrial and pro-survival functions, respectively, in a range of human cancers • ClpP agonism and DRD2 antagonism occurs at nanomolar concentrations • Anti-cancer activity is dependent on ClpP and/or DRD2 depending on tumor type • Downs

  32. Slide 32: ONC206 Monotherapy Activity in Multiple CNS Cancer Models

    32 • Nanomolar activity across CNS tumors, including HGG, medulloblastoma and meningioma • In vitro and in vivo data demonstrates enhanced efficacy data with increasing dose and sustained exposure • Tumor regression and survival extension in transgenic and patient-derived medulloblastoma models ONC2

  33. Slide 33: ONC206 Results in Non-CNS Solid Tumors

    33 • Broadly active across 1088 cancer cell lines representing 25 tumor types with an average IC50 of 562 nM 1 • In vivo results improved with dose intensification in chemo-refractory TNBC, including tumor regressions2 • Improved results relative to dordaviprone in endometrial cancer3 Monotherapy Re

  34. Slide 34: Ongoing Pipeline Development

    34 1. Rapidly Emerging Antiviral Drug Development Initiative Ongoing Pipeline Development • ONC212 GPR132 + ClpP agonist - GLP-tox studies complete, potential to advance to IND, work performed with support from academic grants - Preclinical studies are ongoing to evaluate additional oncology indicat

  35. Slide 35: Corporate Update

    Corporate Update

  36. Slide 36: Potential for Imipridones Beyond Brain Tumors

    36 Potential for Imipridones Beyond Brain Tumors Results of Phase II Study of dordaviprone (ONC201) in Neuroendocrine Tumors at the Cleveland Clinic1 5/14 patients treated > 1 year 11/14 patients experienced tumor regression 1. https://aacrjournals.org/clincancerres/article/28/9/1773/694456/Phase-II

  37. Slide 37: TEMBEXA Deal Term Summary

    37 TEMBEXA is an internally-developed anti-viral program approved by FDA in 2021 and divested to Emergent in an asset sale agreement in 2022. Emergent BioSolutions is an experienced biodefense company collaborating with government agencies to protect public health Terms summary: • $238 million recei

  38. Slide 38: Investment Highlights and Key Catalysts

    38 Investment Highlights and Key Catalysts Dordaviprone U.S. NDA submission planned for Dec ‘24, potential U.S. accelerated approval in 2025  No approved therapies currently in recurrent H3 K27M diffuse glioma, an invariably lethal Grade 4 glioma (World Health Org)  Total addressable market exceed

  39. Slide 39: Chimerix

    Chimerix Corporate Presentation

Chimerix — Investor Presentation (December 2024) on 6ix